Company intelligence / Profile preview

Artisan Pharma

Waltham, Massachusetts, United Statesleadiq.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

Artisan Pharma developed ART‐123, a recombinant human soluble thrombomodulin for the treatment of sepsis-associated DIC. The lead program reached Phase 2 clinical trials to assess safety and efficacy in reducing mortality from DIC complications in sepsis patients. The company was acquired by Asahi Kasei Pharma in November 2011 and became its U.S. subsidiary[3][4][5].

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteins (specifically recombinant human soluble thrombomodulin)
Industry: Biotech

Drug pipeline

1 asset

ART-123

Phase 3

Indications: Disseminated intravascular coagulation, Deep vein thrombosis, Sepsis

Partnerships

Asahi Kasei Pharma Corp.licensing partners for ART‐123

Beyond the preview

Go deeper on Artisan Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artisan Pharma.

Explore the full profile